An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...
Tag: Therapeutics
Bankrupt Sorrento Therapeutics Secures Court Approval for $75M Financing
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced that the U.S. Bankruptcy Court for the Southern District of Texas granted interim approval of Sorrento’s $75 million debtor-in-possession finan...
Halle Berry Opens Up About This ‘Second Act’ Of Her Life Today And Her Involvement In Pendulum Therapeutics
Pendulum Chief Communications Officer Halle Berry. Cayce Clifford For decades now, Academy Award winner Halle Berry has been best known for capturing our hearts and minds up on the big screen with her...
Sorrento Therapeutics Stock Nosedives After Filing Bankruptcy Paperwork
COVID-19 drug and vaccine developer Sorrento Therapeutics Inc (NASDAQ: SRNE) is filing for bankruptcy following a lengthy legal dispute. The biotech submitted its Chapter 11 filing, per an SEC filing,...
Amicus Therapeutics is an ideal spec
Inmode Ltd: “It sells for incredibly cheap. … Frankly, I don’t get it, and that makes me want to look more into it, not just say buy.” Exact Sciences Corp: “They’re...
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12. The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT...
Halo Therapeutics stock drops following weak 2023 outlook
Halozyme Therapeutics Inc. HALO, -10.09% stock fell in the extended session Tuesday after the biotech drug maker’s 2023 forecast disappointed Wall Street. Halozyme shares fell as much as 8% after hour...
Fate Therapeutics Ends Collaboration Deal With Janssen, Cuts Staff
Fate Therapeutics Inc (NASDAQ: FATE) has decided to terminate the collaboration and option agreement with Janssen Biotech Inc, a Johnson & Johnson unit (NYSE: JNJ), on revised terms and conditions...
Now That FDA Approved TG Therapeutics Multiple Sclerosis Treatment, Analyst Are Boosting Price Targets
Wednesday, the FDA approved TG Therapeutics Inc’s (NASDAQ: TGTX) Briumvi (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS). Briumvi is the first and only anti-CD20 monoclonal an...
Viking Therapeutics’ stock rallies after Madrigal shares positive data about its liver drug
Shares of Viking Therapeutics Inc. VKTX, +77.61% jumped 55% in premarket trading on Monday after a company that is also developing a selective thyroid hormone receptor beta agonist as a treatment for ...
Ginkgo Has Hired A New Head Of Biopharma To Disrupt The Gene And Cell Therapies Market
Behzad Mahdavi, Senior Vice President Biopharma Manufacturing & Life Sciences Tools at Ginkgo … [+] Bioworks. Ginkgo Bioworks Cell and gene therapies may be the most anticipated invention of...
Horizon Therapeutics, Coupa Software, Weber and more
Check out the companies making headlines in midday trading. Horizon Therapeutics – Shares of the drugmaker jumped 15.5% after the company announced it has agreed to be acquired by Amgen in a deal valu...
Cramer shares his outlook on Amgen after the Horizon Therapeutics deal
Horizon Therapeutics Plc (NASDAQ: HZNP) is up nearly 15% on Monday after Amgen Inc (NASDAQ: AMGN) revealed plans of buying the biopharmaceutical company for $27.8 billion. What it means for Horizon sh...
Horizon Therapeutics, Coupa Software, Rivian and more
Take a look at some of the biggest movers in the premarket: Horizon Therapeutics (HZNP) – The drugmaker’s shares surged 14.7% in the premarket after it agreed to be bought by Amgen (AMGN) for $1...
Amgen confirms to acquire Horizon Therapeutics in cash deal valued at about $27.8 billion
Amgen Inc. AMGN, -2.42% said Monday it has agreed to acquire Horizon Therapeutics Plc HZNP, +0.39% in an all-cash deal valued at $27.8 billion, confirming earlier reports and a deal that was first moo...
Horizon Therapeutics, Coupa Software, Rivian, and More Stock Market Movers
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...
Marvell Technology, Horizon Therapeutics, DoorDash and more
Marvell Technology Group Source: marvell.com Check out the companies making headlines before the bell: Marvell Technology (MRVL) – The chip maker’s stock slid 4.9% in the premarket after quarter...
CrowdStrike, Horizon Therapeutics, Petco and more
A customer carries a dog near a Petco Animal Supplies shopping bag outside a store in New York. Angus Mordant | Bloomberg | Getty Images Check out the companies making headlines in midday trading. Cro...
Analysts Slash Y-mAbs Therapeutics Price Targets As Uncertainty Looms Over Neuroblastoma Hopeful
On Friday, FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 16 to 0 that Y-mAbs Therapeutics Inc (NASDAQ: YMAB) did not provide sufficient evidence to conclude that omburtamab improves over...
Forma Therapeutics shares jump 50%; here is why
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk. According to the agreement terms, Novo Nordisk will purchase the clinical-st...
Pfizer is acquiring Global Blood Therapeutics
Pfizer Inc (NYSE: PFE) has executed a definitive merger agreement with Global Blood Therapeutics Inc (NASDAQ: GBT), whereby Pfizer will acquire the biopharmaceutical corporation dedicated to the deliv...
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its po...
vTv Therapeutics Shares Jump On Equity Investment
MarketWatch General Motors shares dip premarket after profit falls short of estimates General Motors Co. shares slid lower in premarket trade Tuesday, after the car maker’s second-quarter profit...
Roivant, Pfizer unveil Priovant Therapeutics focused on autoimmune disease treatments, Roivant stock surges
Shares of Roivant Sciences Ltd. ROIV, -2.30% shot up 10.0% in premarket trading Tuesday, after the biopharmaceutical company and drug giant Pfizer Inc. PFE, +0.56% unveiled Priovant Therapeutics, a bi...
Repare Therapeutics stock is down as insiders flock to buy the $30-million RPTX dip
For the most part, biotech stocks have taken a beating this year, along with the broader market. The Nasdaq Biotechnology Index (INDEXNASDAQ: NBI) is down over 26% this year, while the S&P 500 is ...
Repare Therapeutics shares rise by 25% after it announced its collaboration deal with Roche
Repare Therapeutics Inc (NASDAQ: RPTX), a top clinical-stage precision oncology corporation, announced that it’s executed a collaboration and worldwide license deal with Roche for both the commerciali...
Here is Why Turning Point Therapeutics Jumped 110%
Turning Point Therapeutics Inc (NASDAQ: TPTX) jumped 110% after announcing a definitive merger agreement with Bristol Myers Squibb Co (NYSE: BMY). Under the agreement, Bristol Myers Squibb will acquir...
Turning Point Therapeutics shares more than doubled on Friday
Shares of Turning Point Therapeutics Inc (NASDAQ: TPTX) more than doubled on Friday after Bristol-Myers Squibb Co (NYSE: BMY) said it will buy the biotech company for $4.10 billion in cash. Bristol-My...
Fate Therapeutics stocks heads for record selloff after Janssen collaboration terminated and job cuts
Shares of Fate Therapeutics Inc. FATE, -61.18% plunged 56.8% in premarket trading, putting them on track for a record one-day selloff, after the biopharmaceutical company announced the termination of ...